Global Cell Therapy Market

Cell Therapy Market Size, Share, Growth Analysis, By Therapy Type(Allogeneic Therapies (Stem Cell Therapies (Hematopoietic Stem Cell Therapies, Mesenchymal Stem Cell Therapies), Non-Stem Cell Therapies (Keratinocytes & Fibroblast-based Therapies, Others)), By Cell Type(Stem Cell (Bone Marrow, Blood, Umbilical Cord-Derived, Adipose-Derived Stem Cell), By Therapeutic Area(Oncology, Cardiovascular Disease (CVD), Musculoskeletal Disorders, Dermatology), By End User(Hospitals & Clinics, Academic & Research Institutes, and Others), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35H2061 | Region: Global | Published Date: July, 2024
Pages: 157 | Tables: 132 | Figures: 77

Cell Therapy Market News

  • In October 2023, Nekarta, Inc. announced the FDA's approval of an IND application to investigate NKX019, its allogeneic, CD19-directed CAR NK cell therapy candidate, for the treatment of lupus nephritis. 

  • In June 2023, Vertex Pharmaceuticals Incorporated and Lonza announced a joint venture aimed at streamlining the manufacturing process for Vertex's portfolios of investigational stem cell therapies. These therapies are intended to assist individuals with Type 1 Diabetes (T1D), with particular emphasis on advancing the VX-880 and VX-264 programs currently in clinical trials. 

  • In May 2023, Johnson & Johnson entered into a global collaboration and licensing agreement with Cellular Biomedicine Group to advance the development of next-generation CAR-T therapies.

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.



Cell Therapy Market size was valued at USD 3.9 Billion in 2022 and is poised to grow from USD 6.7 Billion in 2023 to USD 190.91 Billion by 2031, growing at a CAGR of 52% during the forecast period (2024-2031).  

The cell therapy market is characterized by intense competition, with numerous key players striving to advance their technologies and expand their market share. Major companies are at the forefront, leveraging their extensive R&D capabilities and robust pipelines to develop innovative therapies. Startups and smaller biotech firms like Adapt immune Therapeutics and Bluebird Bio are also making significant strides, often focusing on niche areas and forming strategic partnerships to enhance their offerings. Additionally, the market sees substantial activity in mergers and acquisitions, as companies seek to consolidate resources, expand their geographical reach, and accelerate product development. The competitive landscape is further shaped by collaborations between research institutions and pharmaceutical giants, aiming to harness cutting-edge technologies and bring novel cell therapies to market more rapidly. 'Thermo Fisher Scientific, Inc. (US) ', 'Merck KGaA (Germany) ', 'Danaher Corporation (US) ', 'Becton, Dickinson, and Company (US) ', 'Lonza Group (Switzerland) ', 'Sartorius AG (Germany) ', 'Nkarta, Inc. (US) ', 'Aurion Biotech (US) ', 'S. BIOMEDICS (Europe) ', 'MEDIPOST (South Korea) ', 'Anterogen Co., Ltd. (South Korea) ', 'JW Therapeutics (China) ', 'JCR Pharmaceuticals Co., Ltd. (Japan) ', 'Johnson & Johnson Services, Inc (US) ', 'Bristol-Myers Squibb Company (US) ', 'Gilead Sciences, Inc. (US) ', 'Novartis AG (Switzerland) ', 'Intellia Therapeutics (US) ', 'Iovance Therapeutics (US) ', 'CRISPR Therapeutics (Switzerland)'

North America emerged as the largest revenue market in 2023, with a share of approximately 58%, and the joint research activities between the research institution and the large pharmaceutical firm. Many developments are being witnessed in the region through these partnerships. For instance, in June 2022, Immatics entered into a collaboration agreement with Bristol Myers Squibb for the development of Gamma Delta Allogeneic Cell Therapy Programs. Government funding also plays an important role in the growth of the market in the United States. For instance, in January 2022, Cellino Biotech said it had secured about $80 million in a Series A funding round from 8VC, Felicis Ventures, and others. The company aims to leverage these funds to increase the availability of stem cell-derived treatments and establish the first independent human cell foundry by 2025. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.


Feedback From Our Clients

Global Cell Therapy Market

Product ID: SQMIG35H2061